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ABSTRACT 
 
Sensitivity analysis is an effective tool for systematically identifying specific perturbations in 
parameters that have significant effects on the behavior of a given biosystem, at the scale 
investigated. In this work, using a two-dimensional, multiscale non-small cell lung cancer 
(NSCLC) model, we examine the effects of perturbations in system parameters which span both 
molecular and cellular levels, i.e. across scales of interest. This is achieved by first linking 
molecular and cellular activities and then assessing the influence of parameters at the molecular 
level on the tumor’s spatio-temporal expansion rate, which serves as the output behavior at the 
cellular level. Overall, the algorithm operated reliably over relatively large variations of most 
parameters, hence confirming the robustness of the model. However, three pathway components 
(proteins PKC, MEK, and ERK) and eleven reaction steps were determined to be of critical 
importance by employing a sensitivity coefficient as an evaluation index. Each of these sensitive 
parameters exhibited a similar changing pattern in that a relatively larger increase or decrease in its 
value resulted in a lesser influence on the system’s cellular performance. This study provides a 
novel cross-scaled approach to analyzing sensitivities of computational model parameters and 
proposes its application to interdisciplinary biomarker studies.  
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1. INTRODUCTION 
 
In the United States, more than 160,000 people die every year of lung cancer, more than breast, 
colon and prostate cancers combined, and non-small cell lung cancer (NSCLC) accounts for 80% 
of them (Jemal et al., 2007). Epidermal growth factor receptor (EGFR) is mutated and 
overexpressed in NSCLC (Hirsch et al., 2003; Paez et al., 2004). A number of different EGFR-
related computational models have been developed with an emphasis on explaining signal-
response relationships between the binding of epidermal growth factor (EGF) to EGFR and the 
activation of downstream molecules (Hatakeyama et al., 2003; Kholodenko et al., 1999; Schoeberl 
et al., 2002). While these models have made successful predictions about the role of different 
molecular processes in the EGFR signaling cascade, they are limited to providing a qualitative 
examination of the underlying network properties and the cellular responses they trigger. Therefore, 
using these models alone, it is difficult to generate a direct quantitative and mechanistic 
understanding of diverse cellular functions such as cell invasion, proliferation, migration and 
adhesion within NSCLC. Furthermore, developing predictive models of human disease requires 
knowledge of different biological levels, including activities within molecular pathways, cells, 
tissues, organs, and even the entire organism, integrated together to help prioritize therapeutic 
targets and design clinical trials (Butcher et al., 2004). 
 
The process of model building and experimental validation is expected to be iteratively performed 
(Di Ventura et al., 2006). To provide more useful knowledge in driving new experiments and 
generating hypotheses for cancer therapy, signaling events critical to determining the output 
behavior of a model must be identified (Swameye et al., 2003). These studies are also a major 
focus of current research in systems biology (Kitano, 2002). Sensitivity analysis has been widely 
accepted as a useful tool to systematically identify specific perturbations that have significant 
effects on system behavior, especially when it is not possible or practical to conduct numerous 
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experiments on the living system itself (Frey and Patil, 2002; van Riel, 2006). A sensitivity 
analysis investigates the effects on the output behavior of a biological system by varying a fixed set 
of governing parameters or by varying possible combinations of parameters within their expected 
ranges. In general, system parameters in a signaling pathway model include initial component 
concentrations and reaction rate constants, both of which can be experimentally measured or 
inferred to construct the model (van Riel, 2006). 
 
To date, a very large number of modeling efforts involving sensitivity analysis have focused 
mainly on the signaling pathway scale within cells (Bentele et al., 2004; Cho et al., 2003; Lee et al., 
2003; Liu et al., 2005; Mahdavi et al., 2007; Martin and Buckland-Wright, 2004; Zhang and 
Rundell, 2006; Zi et al., 2005). Some practical applications on robustness analysis of a system, 
biomarker selection, and drug efficacy evaluation have also been provided (de Pillis et al., 2005; 
El-Samad et al., 2005; von Dassow et al., 2000), which demonstrate the successful extension of the 
technique. In cancer systems biology, some cellular level models have attempted sensitivity 
analysis of different system parameters, e.g. vasculature of tumors (Wijeratne and Hoo, 2007) and 
radiation-induced leukemia (Shuryak et al., 2006). However, to understand the quantitative, 
dynamical properties of a complex biological system such as cancer, analyzing the sensitivity of 
parameters at only the molecular or cellular level is not sufficient. Because cancer cells react and 
respond to, and biological processes take place in, heterogeneous and highly structured 
biochemical environments (Di Ventura et al., 2006), it is necessary to examine the effect of 
perturbations in parameters which span both molecular and cellular levels, and beyond.  
 
We previously developed a two-dimensional (2D) simulation model integrating both molecular and 
cellular levels to examine multicellular dynamics in NSCLC (Wang et al.). An EGFR-ERK 
signaling transduction pathway specific to NSCLC was proposed and the impact of the change in 
extrinsic chemotactic stimulus on tumor expansion rate was tested. Here, we use this modeling 
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platform and employ sensitivity analysis to identify critical pathway components and reaction steps 
and to further test the impact of parameter perturbations on the model output behavior. Like most 
of the previous sensitivity analysis studies established for signaling pathways (Bentele et al., 2004; 
Ihekwaba et al., 2004; Lee et al., 2003; Liu et al., 2005; Zhang and Rundell, 2006; Zi et al., 2005), 
a sensitivity coefficient is applied to our analysis as an index to evaluate the sensitivity of a 
parameter to the model. However, unique to this study, we utilize the tumor expansion rate—a 
cellular or microscopic level behavior—as the main, cross-scale  biological response of the model. 
While confirming the overall robustness of the model, we successfully identified three critical 
pathway components and eleven critical reaction steps, and suggest several potential biomarkers 
that warrant further experimental follow up.  
 
2. METHODS 
 
2.1 NSCLC Simulation Model 
Our previously developed 2D NSCLC model is again employed as the simulation platform in this 
study; therefore, we will only briefly introduce the concept as well as some key development 
methods of the model. Supplementary Figure 1 shows the NSCLC-specific signaling transduction 
pathway and includes the biochemical reactions that we have previously proposed (Wang et al.). 
The model consists of ordinary differential equations composed of 20 components downstream of 
EGF stimulation and 38 corresponding rate constants. Detailed chemical reactions, including rate 
constants and initial concentrations of components, are described in Supplementary Tables 1 and 
2. Two of the components, phospholipase Cγ (PLCγ) and extracellular signal-regulated kinase 
(ERK), are employed to determine two phenotypic traits (proliferation, migration) by comparing 
their rates of change (ROC) of concentration with corresponding thresholds. The following cellular 
phenotypic decision algorithm is then applied to the model: a cell will 1) continue to exhibit its 
previous phenotype if neither of the ROCs of the two components exceed their corresponding 
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thresholds, 2) migrate if only ROCPLC exceeds the threshold of PLCγ, 3) proliferate if only 
ROCERK exceeds the threshold of ERK, and 4) in the case that both of the ROCs exceed their 
corresponding thresholds, migrate if following Rule A (migration advantage rule) or proliferate if 
following Rule B (proliferation advantage rule). It should be noted that Rule A and Rule B are 
artificial rules that we proposed in the absence of any specific experimental data currently available.  
 
Tumor growth dynamics are investigated in a virtual 2D micro-environment with a discrete lattice 
containing 200 x 200 grid points. A blood vessel representing ‘nutrient’ source is located at 
(150,150) and a number of 7 x 7 NSCLC cells are initially positioned in the centre of the lattice. 
When the first cell reaches the nutrient source, the simulation run is terminated and the elapsed 
time steps are used as a measure of tumor expansion rate. Three external chemical diffusive cues, 
EGF, glucose, and oxygen levels, are incorporated into the model and are continuously updated 
throughout the simulation process. Each grid point within the lattice is assigned a concentration 
profile determined by these three external cues by means of normal distribution. The nutrient 
source maintains the highest value of the three cues implicating that it is the most attractive 
location for the chemotactically acting tumor cells. One of the important features of the multiscale 
model is that each cell encompasses a self-maintained molecular interaction network. The 
simulation system records the molecular composite profile for each cell at every time step in order 
to determine the cell’s phenotype for the next step. This essential algorithm establishes the 
connection between molecular and cellular levels. Figure 1 shows the cellular phenotypic decision 
process between two typical time steps. According to our previous findings, Rule A led to a more 
spatially aggressive tumor with a faster tumor expansion rate than that caused by Rule B. A typical 
cell expansion pattern conducted using the reference parameter values is shown in Fig. 2. Tumor 
cells are seen to move toward the nutrient source in the NSCLC model. Having a clinical 
perspective in mind, our interests focus on the more aggressive tumors; hence, sensitivity analysis 
is conducted on the NSCLC model utilizing Rule A. 
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2.2 Sensitivity Analysis 
The method used in the present study belongs to the local sensitivity analysis category which is 
mainly used to evaluate the contribution of individual parameters to the overall performance of a 
system (Ihekwaba et al., 2004). Alternatively, the global sensitivity analysis category encompasses 
methods that can define the relative importance of parameters related to a system. These analyses, 
however, require more computational resources and the use of sampling methods to generate 
random sets of parameter values for simulations. Local and global sensitivity analysis methods 
may be individually appropriate for different systems depending on the purpose of their 
implementation, and a recent comparison study showed rankings of the two types (Zhang and 
Rundell, 2006). In our case, as an initial analysis of the NSCLC model, local sensitivity analysis is 
a reasonable method of investigation because 1) we are able to perform more detailed analysis on 
specific parameters that are of particular interest, and 2) local sensitivity analysis can be applied to 
both linear and non-linear systems (Ingalls and Sauro, 2003). 
 
Within our NSCLC model, molecular and cellular activities are inextricably linked: biological 
responses at the cellular level, such as migration and proliferation, are determined by examining 
the change of pathway component concentrations at the molecular level. This design allows us to 
perform cross-scale analysis on the model. We use a sensitivity coefficient as an index to evaluate 
the effects of perturbations of individual parameter values on the overall system outcome. The 
coefficient is defined by the following equation (Rabitz et al., 1983):  
 
pp
MMS Mp /
/
δ
δ=           (1) 
 
where p represents the parameter that is varied in a simulation and M represents the response of the 
system; δM is the change in M due to δp, the change in p. In our case, M corresponds to the tumor 
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expansion rate, i.e. elapsed simulation time steps, while p corresponds to any of the individual 
parameters, including pathway components and reaction rate constants. The bigger the absolute 
value of sensitivity coefficient, MpS , the more sensitive is the given parameter. 
M
pS  > 1 implies 
that changes in parameter p may have a significant effect on tumor expansion rate M. It is worth 
noting that, using Eq. (1) has certain drawbacks as a result of adopting the expansion rate as M, 
because, as an extreme example, a cell cannot reach the nutrient source in one step due to the 
settings of the model, but p can be set to any positive values in a simulation run. Therefore, p must 
be varied within a finite range, and the accuracy of sensitivity identification decreases as the 
absolute value of pp /δ  increases. That is, the significance of sensitivity coefficients obtained 
using an unrealistically large change in value of a given parameter should not be overestimated in 
determining whether the parameter is critical to the model.  
 
In our analysis, two conditions result in a positive MpS : an increased expansion rate with 
decreasing levels of a parameter, and a decreased expansion rate with increasing levels of a 
parameter. For example, if the expansion rate is increased (which results in decreased elapsed time 
steps, e.g., from M1 to M2, where M2 < M1) and a certain parameter value is decreased from p1 to p2, 
where p2 < p1, then δM is negative and δp is negative, and by using equation 1, the resultant MpS  
will be positive. Similarly, an increased expansion rate with increasing levels of a parameter, and a 
decreased expansion rate with decreasing levels of a parameter result in a negative MpS . That is, the 
sensitivity coefficient is an evaluation index for the parameter’s sensitivity to the model and does 
not directly indicate the tumor’s expansion rate. 
 
The reference parameter values are taken from the literature and are summarized in Tables 1 and 2 
which list the key components selected from the pathway and the 38 rate constants, respectively. 
The initial concentrations of the other components (see Supplementary Fig. 1) are set to zero. To 
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explore critical parameters, the sensitivity coefficient is calculated using Eq. (1) for each parameter 
set, perturbing only one parameter and keeping others fixed at their reference values. Variations of 
each individual parameter should be limited to an expected range; in an effort to cover the entire 
range of possible, albeit not probable, fluctuations in vivo, we investigated an extensive space for 
each parameter (while remaining mindful of the aforementioned limitations of the technique at 
very large variations). 
 
3. RESULTS 
 
The variation ranges for individual parameters, shown in Tables 1 and 2, were set from 0.9-fold (a 
10% decrease) to 100-fold of corresponding reference values (however, variation ranges are 
usually less than 100-fold (Calabrese, 2005)). Each of the variations in the parameters was used as 
the only change of input when running a simulation, and all other parameters were held fixed at 
their reference values. This process was repeated for all parameter values, and the resulting 
sensitivity coefficients were compiled for further analysis. 
 
3.1 Critical Components 
Figure 3 illustrates the sensitivity coefficients of each pathway component with respect to the 
variations listed in Table 1. Protein kinase C (PKC), mitogen-activated protein kinase kinase 
(MEK) and ERK are most sensitive to the model, as seen by their sensitivity coefficients near one, 
followed by less-sensitive EGFR, PLCγ and Raf. Therefore, PKC, MEK and ERK are critical 
components of the pathway (currently) implemented. The peak maxima of sensitivity coefficient 
plots of the three critical components occur at a variation of 1.1-fold of their corresponding 
reference values. At a variation of 2.0-fold, their sensitivity coefficients decrease dramatically to a 
small value, meaning the expansion rate did not deviate much from that of the reference value, 
indicating that the expansion of the system is no longer subject to the increase in these parameter 
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values. We call such ranges of variation that express the sensitive property of a model component 
the “critical area”. In our study, the critical areas for the three components are variations between 
1.1- and 2.0-fold of reference values. 
 
To gain more insight into how small changes in the concentration values of the three components 
will affect the system expansion rate, we performed more detailed analyses on PKC, MEK, and 
ERK. We varied concentration values from 1.0- (but not including 1.0) to 1.2-fold by an 
incremental increase of 0.01, and from 1.2- to 2.0-fold by an incremental increase of 0.1 within 
each component’s critical area. The resulting sensitivity coefficients are shown in Fig. 4. It can be 
seen that sensitivity coefficients of all the three components drop gradually as the variation 
increases. 
 
3.2 Critical Steps 
We conducted further investigations to identify critical steps within the model, calculating 
sensitivity coefficients for each of the 38 rate constants. Table 2 lists for each rate constant the 
sensitivity coefficient (whose absolute values is the largest obtained for the rate constant) and the 
corresponding variation. We find twelve sensitive rate constants (whose maximum absolute 
sensitivity coefficients are equal to 0.9), corresponding to reaction steps: v5, v6, v7, v9, v10, v11, v12, 
v14, and v15 (see Table 2), which are considered to be more critical than others. Again, more 
detailed analyses of these steps were carried out by examining smaller changes in variation. 
Because maximum absolute values of sensitivity coefficients of some rate constants occurred at 
0.9-fold variation, we determined the critical area from 0.1- to 1.0-fold for these rate constants, and 
from 1.0- to 2.0-fold for the remaining constants. The resulting sensitivity analyses are shown in 
Fig. 5. From these detailed tests, the critical reaction steps are further divided into two groups: a 
critical group (CG) in which the maximum absolute value of sensitivity coefficients of a reaction 
step is less than 5.0 and greater than 1.0, and a highly critical group (HCG) if the maximum 
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absolute value is greater than or equal to 5.0. Accordingly, reaction steps, v6, v7, v9, v10 and v11 
belong to CG, and v12, v14 and v16 belong to HCG. Because the maximum absolute value of 
sensitivity coefficients of k5-b (corresponding to v5, see Table 2) is still 0.9 after further study, we 
consider it to be non-critical. Consistent with our previous finding on critical components, v10 (CG), 
v12 (HCG), and v16 (HCG) are reaction steps directly related to PKC, MEK, and ERK, respectively. 
 
4. DISCUSSION 
 
When conducting parameter analysis of a computational cancer model as a means to make correct 
predictions and to guide treatment, focusing on the molecular or the cellular level only may not be 
suitable because cells respond to heterogeneous and highly structured biochemical environments 
(Di Ventura et al., 2006). In a signaling pathway model which functions only on the molecular 
level, it is likely that a wide range of parameters will fit the ultimate signal events (i.e., will lead to 
the same final solution), but they may lead to different cellular responses when examining the 
pathway in different cellular environments. Taking the EGFR-ERK signaling pathway as an 
example, Fig. 6 schematically illustrates the possible difference between molecular and cellular 
scale responses dependent on microenvironmental conditions (‘context-specific’ outcome). On the 
other hand, only environmental (high-level) parameters can be analyzed in cellular models, which 
do not always reveal the mechanisms underpinning the observed phenomena. Our previously 
developed multiscale model for NSCLC investigated the effects of intracellular events on cellular 
responses (Wang et al.). Therefore, using this previously developed in silico platform, we were 
able to conduct this study here to assess the influence of molecular level parameters on a cellular 
level response. The model response utilized was not a behavior of output signals or signal 
activation patterns, but rather the tumor expansion rate (a phenotypic behavior at the cellular level), 
which was influenced by both signaling components and tumor growth environment. To our 
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knowledge, this is the first time to investigate parameter sensitivities of a cancer model, across 
different biological levels.  
 
The analysis results confirmed the robustness of the previously developed NSCLC model. The 
model was capable of tolerating up to 100-fold variation in most parameters, facilitating adaptation 
of the model to different cancer systems without much system-specific readjustment of parameters. 
However, some components such as PKC, MEK and ERK (see Fig. 3) were found to be critical to 
the stability of the model in terms of their influence on the selected microscopic performance 
evaluator. This means that minor quantitative variations in any such sensitive parameter, within its 
critical area, led the model to respond drastically with regards to the tumor’s spatio-temporal 
expansion rate. However, the fact that the critical area for these sensitive parameters was rather 
small further supports the notion of a tightly regulated signaling network. While we are aware of 
the fact that the pathway implemented is incomplete and its context over-simplified, we 
nonetheless argue that for the current setup these critical components can be understood as 
biomarkers because, as their values are altered, the model produces distinct cellular responses 
which may lead to different characteristic disease phenotypes (Frey and Patil, 2002). The 
importance of MEK and ERK determined in our works here is in agreement with another control 
analysis study on a more complex kinetic model of EGF-induced MAPK signaling (Hornberg et al., 
2005). We also note that many experimental and pharmaceutical studies have demonstrated the 
substantial potential of PKC as a biomarker, especially in human breast cancer, colon cancer, and 
NSCLC (Bae et al., 2007; Davidson et al., 1998; Green et al., 2006; Nagashima et al., 2007), as 
well as the use of ERK in NSCLC (Han et al., 2005; Vicent et al., 2004). While MEK has not been 
a large focus in biomarker studies, it does play a significant role in the generic MAPK cascade 
(Wakeling, 2005). The activation and inhibition of MEK result in different signal output in terms 
of strength and duration (Allen et al., 2003; Gollob et al., 2006), therefore, possible use of MEK as 
a biomarker (as a profile, in conjunction with PKC and ERK, or separately) should be 
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experimentally investigated. Intriguingly, recent results in other solid cancers, i.e. gliomas, 
implicating MEK in the phenotypic decision process, seem to corroborate our findings (Demuth et 
al., 2007).  
 
Some pathway components failed to demonstrate critical impact in the current setup, although their 
significance for a variety of cell responses in cancer has been experimentally confirmed (such as 
PLCγ for tumor cell motility (Mouneimne et al., 2004; Piccolo et al., 2002), Raf for tumorigenesis 
(Gollob et al., 2006) and cell differentiation (Hirsch et al., 2006)) which originally led to their 
inclusion in our in silico model. Because PLCγ was used as the key regulating component for 
exploring a migratory phenotypic switch, one would have expected it to have greater control over 
the behavior of the model. A closer look reveals this is a result largely of the selection of the 
designated network performance evaluator (the system outcome). After all, choosing an 
appropriate output target is a challenge in calculating context-specific sensitivity of parameters  
(Aldridge et al., 2006). In this study, we chose the tumor’s expansion rate to be the system 
outcome M in Eq. (1) to suit our clinical perspective. Furthermore, the model examined the rate of 
change of PLCγ, not the PLCγ concentration, in order to process a migration decision, and thereby 
even if the concentration of PLCγ is higher, its rate of change may not be. However, this result also 
confirmed that the assignment of molecular threshold steps does not necessarily predetermine their 
weight on the phenotypic behavior they induce across scales, and that different thresholds (PLCγ 
versus ERK) can have distinctively different impact.  
 
The most interesting finding in our analysis results is that, for both initial component 
concentrations and reaction rate constants, sensitivity coefficient plots of the sensitive parameters 
revealed similar patterns. Each of the sensitive parameters has a critical area, and if a variation 
occurred in that area, the varying parameter values had strong influence on the cancer system’s 
expansion rate which served as our microscopic “read-out”. All sensitivity coefficients decreased 
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with an increase of variation within the critical area. Interestingly, here a very small variation in a 
parameter reference value resulted in a large change on the final output of the model, but 
conversely a relatively large change did not substantially alter model output. Together, this 
suggests a tightly coupled and highly efficient sub-cellular information processing system where 
even minimal modulations in signal strength are sufficient to elicit major phenotypic changes. 
Experimentally, this phenomena has been commonly reported with regards to dose-response 
relationship of human tumor cell lines (see (Calabrese, 2005) for a review). For example, in testing 
responses to transforming growth factor-β (TGF-β) stimulation, a low TGF-β concentration results 
in increased cellular proliferation in prostate carcinoma cell lines (Ritchie et al., 1997). In NSCLC 
cell lines, insulin-like growth factor-I (IGF-I) significantly inhibits cell proliferation at higher 
concentrations (Kodama et al., 2002) Additionally, some in silico pathway models also predict the 
aforementioned sensitivity response in final molecular signaling events (Kharait et al., 2007; Liu et 
al., 2005; Mahdavi et al., 2007).  
 
5. CONCLUSION & FUTURE WORKS 
 
In summary, using a multiscale NSCLC model, this paper presents a innovative approach to 
investigate parameter sensitivities of a cancer model by taking both molecular and cellular levels 
into account. While, overall, the model displayed robustness to relatively large fluctuations, some 
parameters had more impact on the system’s multicellular performance than others. A small 
variation in the reference value of any critical parameter, including three pathway components and 
eleven reaction steps, resulted in a relatively large change in the multicellular output of the model. 
In the future, we plan on simulating a three-dimensional biochemical environment at the cellular 
level which should help provide a more accurate representation of the in vivo situation. At the 
molecular level, while a computational model cannot be a biological representation in every detail, 
integration of other pathways of relevance into the current NSCLC model, such as e.g. 
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PI3K/PTEN/AKT (Vivanco and Sawyers, 2002) and TGF-β (Akhurst and Derynck, 2001), will be 
utilized. Global sensitivity analysis will then be exploited in investigating the possibilities of 
combined effects of parameter variations for a wide range of possible values for all parameters 
simultaneously. While comprehensive analysis strains computing resources, random sets of 
parameter values for simulations can be generated more easily with advanced sampling methods 
and will benefit model analysis. Although still at the beginning, we nonetheless believe that this 
cross-scale sensitivity study provides a novel, useful method in exploring and ranking biomarkers, 
and, more generally, supports the use of such multiscale models in interdisciplinary cancer 
research. 
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CAPTIONS 
Figure 1: Phenotypic decision process for a cancer cell between two typical time steps. 
 
Figure 2: A typical cell expansion pattern in the NSCLC model. Proliferative cells are labeled in 
dark blue, migratory cells in red, quiescent cells in green and dead cells in grey.  
 
Figure 3: The sensitivity coefficients of each selected pathway component with respect to the 
variations listed in Table 1. 
 
Figure 4: The sensitivity coefficients of most sensitive pathway components (PKC, MEK and 
ERK) with respect to the variations from 1.0- to 1.2-fold by an incremental increase of 0.01 (left 
panel) and from 1.2- to 2.0-fold by an incremental increase of 0.1 (right panel). 
 
Figure 5: Plots of sensitivity coefficients for sensitive rate constants. In (a), seven rate constants 
are shown for which the critical area is between 1.0- and 2.0-fold; their values varied from 1.0- to 
1.2-fold by an incremental increase of 0.01 (first and third columns) and from 1.2- to 2.0-fold by 
an incremental increase of 0.1 (second and fourth columns). In (b), five rate constants are shown 
for which the critical area is between 0.1 and 1.0; their values varied from 0.1- to 0.8-fold by an 
incremental increase of 0.1 (first and third columns) and from 0.8- to 1.0-fold by an incremental 
increase of 0.01 (second and fourth columns). 
 
Figure 6: Schematic illustration of how perturbations (a, b, c, ..., n) in one or more sub-cellular 
parameters, p, can yield the same dynamic response at the molecular level, yet may lead to distinct 
responses at the cellular level dependent on the microenvironment. 
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FIGURE 6.  
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TABLE 1. Reference values and variations of individual pathway components. Values are taken 
from the literature (Hatakeyama et al., 2003; Kholodenko et al., 1999; Schoeberl et al., 2002).  
Pathway 
Component 
Reference initial 
concentration [nM] 
Range of 
variation 
EGFR 80 
PLCγ 10 
PKC 10 
Raf 100 
MEK 120 
ERK 100 
  
0.9, 1.0, 2.0, 3.0, 
5.0, 10.0, 20.0, 
30.0, 50.0, 100.0 
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TABLE 2. Reference values and variations of association and dissociation rate constants. Values 
are taken from the literature (Hatakeyama et al., 2003; Kholodenko et al., 1999; Schoeberl et al., 
2002).  
Reaction 
number Rate constant 
Reference 
value 
Range of 
variation 
Maximum absolute value 
of sensitivity coefficient Variation 
k1-a 0.003 -0.07 1.1 v1 
k1-b 0.06 -0.83 0.9 
k2-a 0.01 -0.07 1.1 v2 
k2-b 0.1 -0.83 0.9 
k3-a 1 -0.07 1.1 v3 
k3-b 0.01 0 – 
k4-a 450 0.44 3 v4 
k4-b 50 -0.07 1.1 
k5-a 0.06 -0.07 1.1 v5 
k5-b 0.2 -0.9 0.9 
k6-a 1 0.9 1.1 v6 
k6-b 0.05 0 – 
k7-a 0.3 0.9 1.1 v7 
k7-b 0.006 0 – 
k8-a 1 0 – v8 
k8-b 100 0 – 
k9-a 1 -0.9 0.9 v9 
k9-b 0.03 0.09 2 
k10-a 0.214 0.9 1.1 v10 
k10-b 5.25 0 – 
k11-a 4 0.9 1.1 v11 
k11-b 64 0 – 
k12-a 3.5 0.9 1.1 v12 
k12-b 317 -0.9 0.9 
k13-a 0.058 0 – v13 
k13-b 2200 0 – 
k14-a 2.9 0.9 1.1 v14 
k14-b 317 -0.9 0.9 
k15-a 0.05 0 – v15 
k15-b 60 0.09 2 
k16-a 9.5 0.9 1.1 v16 
k16-b 1.46 × 10
5 -0.9 0.9 
k17-a 0.3 0 – v17 
k17-b 160 0.09 2 
k18-a 16 0 – v18 
k18-b 1.46 × 10
5 0 – 
k19-a 0.27 0 – v19 
k19-b 60 0 – 
   
0.9, 1.0, 2.0, 3.0, 
5.0, 10.0, 20.0, 
30.0, 50.0, 100.0 
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Supplementary Figure 1. Kinetic model of the NSCLC-specific EGFR signaling pathway, 
modified from (Wang et al.). The arrows represent the reactions specified in Supplementary 
Tables 1 and 2 and characterized by reaction rates v1–v19 (green numbers). Each pathway 
component is identified by a specific number (brown numbers). 
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Supplementary Table 1. Kinetic equations and initial concentrations. 
Reactant Molecular variable Initial concentration [nM] Ordinary Differential Equation 
X1 EGF to be varied d(X1)/dt = −v1 
X2 EGFR 80 d(X2)/dt = −v1 
X3 EGF-EGFR 0 d(X3)/dt = v1 − 2v2 
X4 (EGF-EGFR)2 0 d(X4)/dt = v2 + v4 − v3 
X5 EGF-EGFR-P 0 d(X5)/dt = v3 + v7 − v4 − v5 
X6 PLCγ 10 d(X6)/dt = v8 − v5 
X7 EGF-EGFR-PLCγ 0 d(X7)/dt = v5 − v6 
X8 EGF-EGFR-PLCγ-P 0 d(X8)/dt = v6 − v7 
X9 PLCγ-P 0 d(X9)/dt = v7 − v8 − v9 − v10 
X10 PLCγ-P-I 0 d(X10)/dt = v9 
X11 PKC 10 d(X11)/dt = −v10 
X12 PKC* 0 d(X12)/dt = v10 − v11 
X13 Raf 100 d(X13)/dt = −v11 
X14 Raf* 0 d(X14)/dt = v11 −v12 −v14 
X15 MEK 120 d(X15)/dt = v13 − v12 
X16 MEK-P 0 d(X16)/dt = v12 + v15 − v13 − v14 
X17 MEK-PP 0 d(X17)/dt = v14 − v15 − v16 − v18 
X18 ERK 100 d(X18)/dt = v17 − v16 
X19 ERK-P 0 d(X19)/dt = v16 + v19 − v17 − v18 
X20 ERK-PP 0 d(X20)/dt = v18 − v19 
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Supplementary Table 2. Kinetic parameters. Concentrations and the Michaelis-Menten constants 
(K4, K8, and K11–K19) are given in [nM]. First- and second-order rate constants are given in [s-1] 
and [nM-1 · s-1], respectively. V4, V8, and V11–V19 are expressed in [nM · s-1]. 
Reaction 
number Equation Kinetic parameter Reference 
v1 k1 · X1 · X2 − k-1 · X3 k1=0.003 k-1=0.06 [1] 
v2 k2 · X3 · X3 − k-2 · X4 k2=0.01 k-2=0.1 [1] 
v3 k3 · X4 − k-3 · X5 k3=1  k-3=0.01 [1] 
v4 V4 · X5 / (K4 + X5) V4=450 K4=50 [1] 
v5 k5 · X5 · X6 − k-5 · X7 k5=0.06  k-5=0.2 [1] 
v6 k6 · X7 − k-6 · X8 k6=1  k-6=0.05 [1] 
v7 k7 · X8 − k-7 · X5 · X9 k7=0.3 k-7=0.006 [1] 
v8 V8 · X9 / (K8 + X9) V8=1  K8=100 [1] 
v9 k9 · X9 − k-9 · X10 k9=1 k-9=0.03 [1] 
v10 k10 · X9 · X11 − k-10 · X12 k10=0.214 k-10= 5.25 Estimate 
v11 V11 · X12 · X13/ (K11 + X13) V11=4 K11=64 [2] 
v12 V12 · X14 · X15 / [K12 · (1 + X16 / K14) + X15] V12=3.5 K12=317 [3] 
v13 V13 · X16 / [K13 · (1 + X17 / K15) + X16] V13=0.058 K13=2200 [4] 
v14 V14 · X14 · X16 / [K14 · (1 + X15 / K12) + X16] V14=2.9 K14=317 [4] 
v15 V15 · X17 / [K15 · (1 + X16 / K13) + X17] V15=0.058 K15=60 [4] 
v16 V16 · X17 · X18 / [K16 · (1 + X19 / K18) + X18] V16=9.5 K16=1.46 × 105 [4] 
v17 V17 · X19 / [K17 · (1 + X20 / K19) + X19] V17=0.3  K17=160 [4] 
v18 V18 · X17 · X19 / [K18 · (1 + X18 / K16) + X19] V18=16  K18=1.46 × 105 [4] 
v19 V19 · X20 / [K19 · (1 + X19 / K17) + X20] V19=0.27 K19=60 [4] 
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